Publications by authors named "Jeff Sharman"

Claim this Profile
E
Erratum: Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.
Franck Morschhauser, Gilles Salles, Laurie H Sehn, Alex F Herrera, Jonathan W Friedberg, Jeff P Sharman

J Clin Oncol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.
Franck Morschhauser, Gilles Salles, Laurie H Sehn, Alex F Herrera, Jonathan W Friedberg, Jeff P Sharman

J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to: Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial.
Jeff P Sharman, Bin Liu, Denise Y Wang, Ching Ching Leow, Paul M Barr

J Clin Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN.
Jeff P Sharman, Miklos Egyed, Wojciech Jurczak, Alan Skarbnik, Krish Patel

Blood· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).
Jeff P Sharman, Talha Munir, Sebastian Grosicki, Lindsey E Roeker, John M Burke

J Clin Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study.
Carrie Thompson, Marek Trněný, Franck Morschhauser, Gilles A Salles, Patrick M Reagan, Jeff P Sharman

Blood· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zanubrutinib is well tolerated and effective in patients with CLL/SLL intolerant of ibrutinib/acalabrutinib: updated results.
Mazyar Shadman, John M Burke, Jennifer Cultrera, Habte A Yimer, Syed F Zafar, Jeff P Sharman

Blood Adv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).
Jeff P Sharman, Talha Munir, Sebastian Grosicki, Lindsey E Roeker, John M Burke

J Clin Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).
Jeff P Sharman, Talha Munir, Sebastian Grosicki, Lindsey E Roeker, John M Burke

J Clin Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Care Coordination for Mosunetuzumab Therapy in Patients With Follicular Lymphoma in Community Practices: Learnings From the MorningSun Study Investigators.
Tara Graff, Ian Flinn, Jeff P Sharman, Steven Liu, Bertrand M Anz

Cancer Med· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subgroup analysis of older patients ≥60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study.
Bei Hu, Patrick M Reagan, Laurie H Sehn, Jeff P Sharman, Mark Hertzberg

Blood Adv· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemotherapy-free treatment with acalabrutinib can benefit patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who were never treated before: a plain language summary of the ELEVATE-TN study.
Jeff P Sharman, Shweta Hakre

Future Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia.
Jeff P Sharman, Miklos Egyed, Wojciech Jurczak, Alan Skarbnik, John M Pagel

Leukemia· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL.
Yuliya Linhares, Cesar O Freytes, Mohamad Cherry, Carlos Bachier, Michael Maris, Jeff P Sharman

Blood Adv· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current Approaches and Novel Agents in the Treatment of Chronic Lymphocytic Leukemia.
Bruce D Cheson, Jeff P Sharman

JCO Oncol Pract· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Treatment Patterns and Outcomes by Line of Therapy and Race in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated in the United States: Results From the Final Analysis of the Prospective, Observational, informCLL Registry.
Nilanjan Ghosh, Jeff P Sharman, Meghan Gutierrez, Wasiulla Khan, Zaina P Qureshi

Clin Lymphoma Myeloma Leuk· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pirtobrutinib combinations in CLL.
Jeff P Sharman

Blood· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of ventricular arrhythmias and sudden death from prospective, randomized clinical trials of acalabrutinib.
Jeff P Sharman, Paolo Ghia, Paulo Miranda, Naghmana Bajwa, Simon Rule

Br J Haematol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.
Linlin Xu, Mazyar Shadman, Ian W Flinn, Moshe Y Levy, Ryan Porter, Jeff P Sharman

Haematologica· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trials.
Matthew S Davids, Jeff P Sharman, Paolo Ghia, Jennifer A Woyach, Toby A Eyre

Blood Adv· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Six-year update of the ELEVATE-TN study on acalabrutinib.
Jeff Sharman

Clin Adv Hematol Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality-adjusted survival time without symptoms or toxicity of acalabrutinib with or without obinutuzumab in patients with treatment-naive chronic lymphocytic leukemia.
Jeff P Sharman, Paulo Miranda, Jack Roos, Ugochinyere Emeribe, Ling Cai

Leuk Lymphoma· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial.
Yuqin Song, Hervé Tilly, Shinya Rai, Huilai Zhang, Jie Jin, Jeff P Sharman

Blood· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Obinutuzumab Can Be Administered as a 90-minute Short Duration Infusion in Patients With Previously Untreated Follicular Lymphoma: GAZELLE End of Induction Analysis.
Miguel A Canales, Thomas A Buchholz, Jaisson A P Bortolini, Laura M Fogliatto, Takayuki Ishikawa, Jeff P Sharman

Hemasphere· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A real-world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first-line (1L) treatment for patients with chronic lymphocytic leukaemia (CLL) in the United States.
Anthony Mato, Boxiong Tang, Soraya Azmi, Keri Yang, Yi Han, Jeff P Sharman

EJHaem· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis